Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00405249 · ClinicalTrials.gov registry record · Phase 2
Safety Study of Elvucitabine in HIV-1 Subjects
A Phase 2 study, sponsored by Thomas Jefferson University.
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT00405249: Completed Phase 2 study, sponsored by Thomas Jefferson University.
NCT00405249 is a Phase 2 study that has completed, run by Thomas Jefferson University. The registered enrollment target is 5 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00405249, a Phase 2 study, has completed, sponsored by Thomas Jefferson University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of this 28 day study is to assess the viral kinetics and safety of elvucitabine.
Interventions
- DRUG elvucitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2006-09 |
| Est. Completion | 2006-11 |
| Phase | Phase 2 |
What the finished NCT00405249 record still lists
NCT00405249 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 1 intervention - of which elvucitabine is the first listed.
NCT00405249 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00405249 about?
NCT00405249 is a clinical study titled "Safety Study of Elvucitabine in HIV-1 Subjects". The purpose of this 28 day study is to assess the viral kinetics and safety of elvucitabine.
What is the current status of trial NCT00405249?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2006-09. Estimated completion is 2006-11.
What interventions are being tested in trial NCT00405249?
The interventions under investigation include: elvucitabine (DRUG).
Who is sponsoring clinical trial NCT00405249?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00405249's enrollment target sits among peer trials
5 2000th of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia